非小细胞肺癌的分子靶向治疗研究进展

肺癌是全球最常见的几种恶性肿瘤之一.近年来, EGFR、EML4-ALK、K-Ras、BRAF、C-MET、PIK3CA等越来越多的癌驱动基因被发现,以EGFR-TKIs为代表的靶向药为肺癌临床治疗带来新进展,但是大部分患者经靶向治疗后都会产生耐药,疗效仍不能满意.因此,基于肺癌基因驱动的机制探索及多靶点联合治疗是未来研究的方向.

Research progress on molecular targeted therapy of non-small cell lung cancer

Non-small cell lung cancer (NSCLC) is one of the most common causes of death.In recent years,molecular targeted therapy represented by epidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) has been successfully utilized in the treatment of NSCLC.However,the efficacy for most molecular targeted therapy is weakened due to secondary resistance.This article mainly summarized the research progress of the molecular targeted therapy aiming at different target spots.